Remdesivir

Remdesivir (GS-5734) is a new antiviral drug in the nucleotide analog category. It is not currently approved globally for any indication. With the deepening of research, it was discovered that the antiviral effect of Remdesivir is not limited to filamentous viruses such as Ebola virus, and it also has inhibitory effects on a variety of viruses such as coronavirus. The U.S. Food and Drug Administration (FDA) reviewed the company's application for an investigational new drug (IND) for Remdesivir to treat Covid-19, and granted investigational new drug authorisation to study the drug in February 2020.